Click Therapeutics

Click Therapeutics develops and commercializes software as medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults.

Click Therapeutics headquartered in New York, New York, United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical, Medical Device, Therapeutics sector. The company focuses on Biotechnology and has secured $227.1B in funding across 240 round(s). With a team of 101-250 employees, Click Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Convertible Note - Click Therapeutics, raised $1.8M. Discover more about their projects, partnerships, and impact on our platform.